Use of Response-Adapted Hypofractionated Radiation Therapy to Potentiate the Systemic Immune Response to Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 13 Jun 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 13 Jun 2018 Planned primary completion date changed from 31 Dec 2018 to 31 Dec 2019.